Fiche centre
University of Miami
Miami — United States
Essais liés26clinical trials
VilleMiamilocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06667908
Essais cliniques associés
26| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| NRTX-1001 | Épilepsie | Phase 3 | NCT05135091 | Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy)) | RECRUITING |
| Empagliflozin | Maladie rénale chronique | Phase 3 | NCT07107945 | A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) | ACTIVE_NOT_RECRUITING |
| Vicadrostat | Insuffisance cardiaque | Phase 3 | NCT06424288 | A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure | RECRUITING |
| ianalumab s.c. q4w | Lupus | Phase 3 | NCT05126277 | SIRIUS-LN — Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | ACTIVE_NOT_RECRUITING |
| SPN-817 | Épilepsie | Phase 2 | NCT06798896 | RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures | RECRUITING |
| AAV2-GDNF gene therapy | Parkinson | Phase 2 | NCT06285643 | A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD) | ACTIVE_NOT_RECRUITING |
| JNJ-90301900 | Cancer | Phase 2 | NCT06667908 | CONVERGE — A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC) | RECRUITING |
| Lab Assay for seven genetic variants for Parkinson's Disease | Parkinson | À vérifier | NCT04994015 | Parkinson's Foundation PD GENEration Genetic Registry | RECRUITING |
| BHV-7000 | Épilepsie | Phase 2/3 | NCT06132893 | RISE 2 — A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | ACTIVE_NOT_RECRUITING |
| PGB2 — Phenotype, Genotype and Biomarkers 2 | Sclérose latérale amyotrophique | À vérifier | NCT04875416 | PGB2 — Phenotype, Genotype and Biomarkers 2 | ACTIVE_NOT_RECRUITING |
| Phenotype, Genotype & Biomarkers in ALS and Related Disorders | Sclérose latérale amyotrophique | À vérifier | NCT02327845 | Phenotype, Genotype & Biomarkers in ALS and Related Disorders | ACTIVE_NOT_RECRUITING |
| TRIAL READY (Clinical Trial Readiness) | Sclérose latérale amyotrophique | À vérifier | NCT03912987 | TRIAL READY (Clinical Trial Readiness) | ACTIVE_NOT_RECRUITING |
| CAPTURE-ALS — Clinical Procedures to Support Research in ALS | Sclérose latérale amyotrophique | À vérifier | NCT03489278 | CAPTURE-ALS — Clinical Procedures to Support Research in ALS | RECRUITING |
| VHB937 | Sclérose latérale amyotrophique | Phase 2 | NCT06643481 | ASTRALS — A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS) | ACTIVE_NOT_RECRUITING |
| Acoramidis | Alzheimer | Phase 3 | NCT06563895 | Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant | RECRUITING |
| TREAT-MS — Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial | SEP | Non applicable | NCT03500328 | TREAT-MS — Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial | ACTIVE_NOT_RECRUITING |
| COYA 302 | Sclérose latérale amyotrophique | Phase 2/3 | NCT07161999 | ALSTARS — Study of COYA 302 for the Treatment of ALS | ACTIVE_NOT_RECRUITING |
| Standard lymphodepletion regimen | Myasthénie | Phase 2/3 | NCT06193889 | KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis | RECRUITING |
| Vamorolone | Myopathies | À vérifier | NCT06564974 | DMD-001 SUMMIT — Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT | RECRUITING |
| Partial Rebreathing Device | Migraine | Non applicable | NCT05546385 | PAREMA1 — PArtial REbreathing for Migraine With Aura 1 | TERMINATED |
| extended release metformin | Alzheimer | Phase 2/3 | NCT04098666 | MAP — Metformin in Alzheimer's Dementia Prevention | ACTIVE_NOT_RECRUITING |
| Ocrelizumab | SEP | Phase 3 | NCT05269004 | OLERO — A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Interferon beta-1a | SEP | Phase 3 | NCT01892722 | Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Atogepant 60 mg | Migraine | Phase 4 | NCT06972056 | Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study | RECRUITING |
| Prednisone | Myasthénie | Phase 3 | NCT00995722 | Efficacy of Prednisone In the Treatment of Ocular Myasthenia | TERMINATED |
| Zilucoplan | Sclérose latérale amyotrophique | Phase 2/3 | NCT04297683 | HEALEY ALS Platform Trial - Master Protocol | ACTIVE_NOT_RECRUITING |